Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase I, Dose-Escalation Study Evaluating Two Dosing Schedules of PI3-Kinase Inhibitor (GDC-0941) in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

NCT00876109 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00876109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00876109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase I, Dose-Escalation Study Evaluating Two Dosing Schedules of PI3-Kinase Inhibitor (GDC-0941) in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2007
Completion date
November 30, 2013
Enrollment
108 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

solid cancers